Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2026

As of March 31, 2026 and December 31, 2025, the Company had reserved common stock, on an as-if converted basis, for issuance as follows (in thousands):


	March 31, 2026	December 31, 2025
K2 Warrants	170	170
Pre-Funded Warrants	7,722	4,622
Stock options issued and outstanding from 2024, 2019 Equity Incentive Plan and Inducement Plan	7,078	5,385
Shares available for future grant from 2024 Equity Incentive Plan and Inducement Plan	877	975
Total	15,847	11,152
The reserved common stock in the table above does not include (i) the number of shares of the Company’s common stock issuable upon conversion of the remaining amount of the Conversion Amount specified within the Amended Loan Agreement (see Note 4), (ii) the variable number of shares issuable pursuant to conversion of amounts funded under the Convertible Grant Agreement (see Note 4), and (iii) the variable number of shares issuable pursuant to terms of the asset purchase agreement, dated May 31, 2025, between the Company and Chase Therapeutics Corporation.